Antiviral agents directed against respiratory syncytial virus

Patent metadata

Field	Value
Publication number	US-10213413-B2
Application number	US-201515523995-A
Country	US
Kind code	B2
Filing date	Nov 5, 2015
Priority date	Nov 6, 2014
Publication date	Feb 26, 2019
Grant date	Feb 26, 2019

Abstract

The present invention relates to N1-benzyl substituted pyrazoles as antiviral agents directed against respiratory syncytial virus.

First claim

The invention claimed is:

1. A method for treating an infection by respiratory syncytial virus (RSV), comprising administering to a subject an agent, wherein said agent is represented in formula (I):

wherein :
R1 and R2 are identical or different and are independently chosen among hydrogen, hydroxyl, halogen, haloalkyl, alkyl, aryl, arylalkyl, nitro, cyano, amino, alkoxy, alkoxyalkyl, heteroaryl, cycloalkyl and heterocyclyl; and
R3 and R4 are identical or different and are independently chosen among carboxylate, ester, substituted or non-substituted alkyloxycarbonyl, halogen, haloalkyl, alkyl, aryl, arylalkyl, nitro, cyano, amino, alkoxy, alkoxyalkyl, heteroaryl, cycloalkyl, heterocyclyl, boronate, phosphate, phosphonate, sulfinyl, sulfonyl, sulfonate, and sulfonamino, sulfonamido.

2. The method according to claim 1 , wherein R3 and R4 are identical and are both carboxylate.

3. The method according to claim 1 , wherein R1 and R2 are identical or different and are independently a halogen independently selected from the group consisting of: fluorine (F), chlorine (Cl), bromine (Br), and iodine (I).

4. The method according to claim 1 , wherein R1 and R2 are identical and are both hydrogen.

5. The method according to claim 1 , wherein R1 is fluorine and R2 is hydrogen.

6. The method according to claim 1 , wherein R1 is bromine and R2 is hydrogen.

7. The method according to claim 1 , wherein R1 is hydrogen and R2 is chlorine.

8. The method according to claim 1 , wherein R1 and R2 are identical and are both chlorine.

9. The method according to claim 1 , further comprising administering an antiviral agent with the agent of formula (I) as a combined preparation for simultaneous, separate or sequential, wherein said antiviral agent is selected from the group consisting of acyclovir, cidofovir, docosanol, famciclovir, foscarnet, fomivirsen, ganciclovir, idoxuridine, penciclovir, peramivir, trifluridine, valacyclovir, vidarabine, lamivudine, and ribavirin.

Assignees

• Centre Nat Rech Scient
• Agronomique Inst Nat Rech
• Pasteur Institut
• Univ Paris Sud
• Institut National De La Rech

Inventors

• Sizun Christina
• Duquerroy Stéphane
• Eleouet Jean-François
• Rey Felix
• Schwok Anny Slama
• Desmaele Didier
• Couvreur Patrick
• Tarus Bogdan

Classifications

• A61P31/14

  for RNA viruses · CPC title

• A61K31/7056

  containing five-membered rings with nitrogen as a ring hetero atom · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title

• A61K31/415 Primary

  1,2-Diazoles · CPC title

• A61K31/675

  having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate · CPC title